Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer
Authors:
- Junhao ChenJCJunhao Chen
- Yuanzhi FuYFYuanzhi Fu
- Zhongsong ZhangZZZhongsong Zhang
- Junxian ZhaoJZJunxian Zhao
- Jieming ZuoJZJieming Zuo
- Xinni YeXYXinni Ye
- Qiao XiongQXQiao Xiong
- Zuqing NieZNZuqing Nie
- Haonan DongHDHaonan Dong
- Hongjin ShiHSHongjin Shi
- Zhiyong TanZTZhiyong Tan
- Chengjie WangCWChengjie Wang
Open Access
- 1 December 2025
- journal article
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 20, 15235-15275
Abstract
Bladder cancer (BC) is a prevalent urinary malignancy characterized by high recurrence rates and suboptimal long-term outcomes from traditional treatments such as surgery, chemotherapy, and radiotherapy. T-cell-based immunotherapy has emerged as a promising approach, harnessing T cells’ capacity to target and destroy tumor cells, yet it faces challenges from the immunosuppressive tumor microenvironment (TME), immune evasion, and T-cell exhaustion. Nanomaterials offer innovative solutions by enabling targeted delivery of antigens, checkpoint inhibitors, and immunomodulators; remodeling the TME through metabolic interventions (eg, hypoxia alleviation and adenosine reduction); and enhancing T-cell infiltration and persistence with stimulus-responsive systems like pH-sensitive nanoparticles and biomimetic vesicles. This review systematically examines nanomaterial integration to amplify T-cell-mediated immunity in BC, covering T-cell origins, differentiation (eg, CD8+ cytotoxic and CD4+ helper subsets), roles in the TME, and exhaustion mechanisms driven by factors like PD-1 and TOX. We discuss key strategies including direct immune enhancement via immunogenic cell death induction, metabolic reprogramming to optimize T-cell function, and sustained activation for improved persistence. In conclusion, these nanomaterial-enhanced therapies address critical barriers, promoting precise and synergistic immune responses. Future prospects highlight AI-driven designs, personalized medicine, and clinical translation to tackle heterogeneity, biosafety, and resistance for durable BC remission.Keywords
This publication has 237 references indexed in Scilit:
- Virulence‐Free Reconstituted Synthetic Nanopathogen Empowered by Timely‐Activating TLR Agonist Promotes Heterologous Cancer Immunotherapy with Depletion of Tumor‐Specific Treg CellsAdvanced Functional Materials, 2024
- Light‐Driven Green‐Fabricated Artificial Intelligence‐Enabled Micro/Nanorobots for Multimodal Phototherapeutic Management of Bladder CancerAdvanced Healthcare Materials, 2024
- In Vivo Stimulation of Therapeutic Antigen‐Specific T Cells in an Artificial Lymph Node MatrixAdvanced Materials, 2024
- Drug‐Loaded Bacillus Calmette–Guérin Bacteria for Immuno‐Chemo Combo Therapy in Bladder CancerAdvanced Materials, 2024
- Nanoengineering Calcium Peroxide‐Based Site‐Specific Delivery Platform to Efficiently Activate the cGAS‐STING Pathway for Cancer Immunotherapy by Amplified Endoplasmic Reticulum StressAdvanced Functional Materials, 2024
- Targeting DNA Damage and Repair Machinery via Delivering WEE1 Inhibitor and Platinum (IV) Prodrugs to Stimulate STING Pathway for Maximizing Chemo‐Immunotherapy in Bladder CancerAdvanced Materials, 2023
- X‐ray‐Induced Release of Nitric Oxide from Hafnium‐Based Nanoradiosensitizers for Enhanced Radio‐ImmunotherapyAdvanced Materials, 2023
- Nanomaterials for NIR‐II Photoacoustic ImagingAdvanced Healthcare Materials, 2022
- Risk for second bladder and rectal malignancies from cervical cancer irradiationJournal of Applied Clinical Medical Physics, 2021
- Development of an In Situ Cancer Vaccine via Combinational Radiation and Bacterial‐Membrane‐Coated NanoparticlesAdvanced Materials, 2019